Objective: This study aims to estimate the prevalence of thyroid diseases and anti-TPO status. We searched for an association among presence of immune reconstitution and use of stavudine, didanosine and protease inhibitors with thyroid diseases. Materials and methods: A cross-sectional study was performed to analyze the records of 117 HIV-infected patients who had their CD4 + cell count, viral load, anti-TPO, TSH and free T 4 levels collected on the same day. Immune reconstitution was considered in those whose T CD4 + count was below 200 cells/mm³, but these values increased above 200 cells/mm³ after the use of antiretrovirals. The odds ratio obtained by a 2x2 contingency table and a chi-square test were used to measure the association between categorical variables. Results: The prevalence of thyroid disease was 34.18%; of these, 4.34% were positive for anti-TPO. There was an association of risk between stavudine use and subclinical hypothyroidism (OR = 4.19, 95% CI: 1.29 to 13.59, X² = 6.37, p = 0.01). Immune reconstitution achieved protection associated with thyroid disease that was near statistical significance OR = 0.45, 95% CI: 0.19 to 1.04, X² = 3.55, p = 0.059.
INTRODUCTION
A IDS is an emerging disease and is one of the largest health problems today because of its pandemic status and severity characteristics. This disease is mainly characterized by a progressive loss of CD4 + T lymphocytes (CD4 + ), which cause immunosuppression and involvement by opportunistic diseases. The natural history of AIDS has been altered considerably by high activity antiretroviral therapy (HAART), which prevents the evolution of the loss of CD4 + to its final stage. Along with prevention campaigns, HAART contributes to the decline of the transmission and stabilization of the epidemic in many countries (1) .
Nevertheless, several complications have been reported with the use of HAART, among them are hypertriglyceridemia, lipodystrophy, type 2 diabetes mellitus, gonadal dysfunction, and osteoporosis (2) . The mechanism by which HAART causes these changes has not been fully elucidated (3) (4) (5) (6) . Another complication is immune reconstitution inflammatory syndrome (IRIS). This condition occurs in some patients receiving HAART who develop clinical deterioration by the reestablishment of immunity despite high CD4 + counts and a low plasma viral load. Immune reconstitution (IR) can be defined as an increased CD4 + count above 200 cells/mm 3 in subjects who previously had CD4 + counts lower than 100-200 cells/mm 3 (7) . The development of autoimmune diseases in HIV patients is increasing (8, 9) . HAART promotes increased patient survival and IR, which could be factors that contribute to autoimmunity. A suggested mechanism of molecular mimesis involves an opportunistic infectious agent that generates an autoimmunity trigger in IRIS or immunodeficient patients (10) (11) (12) . In immunodeficient patients, as soon as the CD4 + cells are depleted, autoimmune diseases can be mediated by CD8 + T lymphocytes (13) .
It is possible to relate the stages of HIV infection with the development of autoimmune diseases, which may arise during an acute viral infection (phase I). Autoimmune diseases also occur at the stage of clinical latency, and even without the overt manifestation of AIDS, there is a progressive decline of CD4 + cells (phase II). When the CD4 + count becomes profoundly low, autoimmune diseases related to CD4
+ cells are more difficult to develop (phase III). After the initiation of HAART, IR occurs with increased CD4
+ cells in addition to altered immune regulation, which may lead to autoimmune disease (stage IV) (13) .
HIV-infected patients have a high overall frequency of autoantibodies, which may be generated as a direct effect of the virus in the endothelium, synovial fluid and hematopoietic cells, leading to the enchantment of the cytotoxic activity of immune cells and autoantigen expression. Increased autoantibody expression, in most cases, is associated with lower CD4
+ cell counts and increased mortality without a relationship with the clinical expression of autoimmune diseases (13, 14) . Graves' disease, rheumatoid arthritis and, rarely, Hashimoto's thyroiditis were reported as complications of IR (15) (16) (17) .
Specifically in autoimmune thyroid disease, the prevalence of primary hypothyroidism in AIDS is higher compared with the general population; however, it is not necessarily associated with autoimmunity. The most common cause of primary hypothyroidism in the population is Hashimoto's thyroiditis, which has a prevalence of 0.3% (18, 19) . Among HIV-infected individuals, the prevalence of primary hypothyroidism is approximately 2.6% (20) (21) (22) .
The prevalence of subclinical hypothyroidism in patients infected with HIV who were not treated varies between 8% and 10%, with a higher propensity in men. Among HAART users, the prevalence reaches up to 12.6%. Naive patients have a higher prevalence of subclinical hypothyroidism shortly after beginning HAART compared with those who have already been on HAART for at least 1 year, suggesting that thyroid dysfunction associated with medication is acute (23) .
A possible manifestation of hypothyroidism in AIDS is dysfunction in the basal secretion of thyroid stimulating hormone (TSH) or central hypothyroi dism. The evaluation of TSH in patients with HIV demonstrates a significant reduction of the nocturnal peak at midnight, which is considered to be a sensitive index for evaluating central hypothyroidism (24) . Another manifestation consistent with central dysfunction is the presence of isolated low levels of TSH with normal free T 4 (FT 4 ). This condition was found in 1.3 to 6.8% of HIV-infected individuals, especially those in advanced disease stages (20, (25) (26) (27) (28) . However, administration of exogenous TSH releasing hormone (TRH) did not alter the response of TSH among individuals with low FT 4 , making hypothalamic or pituitary insufficiency the least likely scenario (29) . Therefore, the clinical significance of a low FT 4 levels is not clear because these patients did not experience a higher frequency of hypothyroidism symptoms compared with control subjects. Thyroid function tests may be requested annually, but levothyroxine therapy is not recommended (30) .
Euthyroid sick syndrome is characterized by normal or low FT 4 levels, low T 3 levels, elevated reverse T 3 (rT 3 ) levels and low or normal TSH levels (31) . This is a physiological adaptive phenomenon of the body to conserve energy during periods of extreme stress and during an infection. HIV-infected patients characteristically have increased resting energy expenditure combined with a loss of appetite and subsequent weight loss. The mechanism involved is the reduction in peripheral conversion of T 4 to T 3 , with accumulation of the inactive metabolite rT 3 . The degree of rT 3 elevation and T 3 and T 4 suppression depends on the severity of the disease or stress. The euthyroid sick syndrome recovery phase can be observed with a transient increase in TSH and normal FT 4 and T 3 levels. Before the HAART era, this disturbance was a common feature of terminal phase AIDS patients (32) .
Thyroid dysfunction among HIV-infected individuals after HAART had an increased prevalence and is linked in most cases to asymptomatic patients, particularly those with subclinical hypothyroidism. Although the mechanism is not clear, stavudine has been suggested as a direct intervening agent in the production and/ or metabolism of thyroid hormones, suggesting the need for monitoring thyroid function in HIV patients who have been treated with this medicine (25, 28, 29) . Drug interactions between protease inhibitors and levothyroxine have also been reported through a shared glucuronidation metabolic pathway. The frequency and clinical impact of these interactions are not known (33) . Patients whose CD4 + counts were below 200 cells/mm³ but the values of which increased above 200 cells/mm³ after HAART were included in the IR group. The reference range for TSH was established as normal between 0.5 to 4.5 μUI/L, increased > 4.5 μUI/L, and decreased < 0.5 μUI/L. The reference range for FT 4 was established as normal between 0.8 to 1.9 ng/dL, increased > 1.9 ng/dL, and decreased < 0.9 ng/dL. Anti-TPO levels were classified as normal if they were below 35 μUI/mL.
MATERIALS AND METHODS

Cross
Descriptive analyses (means and frequencies) were analyzed using SPSS 17 software. Association measurements among categorical variables, such as the use of stavudine, didanosine and protease inhibitors, and the presence of IR and thyroid diseases were analyzed in a 2x2 contingency table by measuring the odds ratio (OR). We performed the uncorrected chi-square test (X²) using the significance value (α) of 0.05 and degrees of freedom = 1, which corresponded to a critical value of 3.84. The Epi Info 7 program was used for this statistical analysis.
RESULTS
After a descriptive and frequency evaluation, the results regarding gender, age, time since diagnosis and antiretroviral status are demonstrated in table 1. The mean
CD4
+ cell count did not differ between the groups, which were ranked according to thyroid dysfunction and measured by TSH levels according to the data contained in table 2. Among 100 patients, 4% had increased anti-TPO (1% were diagnosed as subclinical hypothyroidism, 1% as secondary hyperthyroidism, and 2% had normal TSH and FT 4 ).
Using the 117 patients selected for an unrelated anti-TPO analysis, thyroid disease diagnoses, as measured by thyroid function tests and frequency analyses, are contained in table 3. 
DISCUSSION
Cross-sectional studies have the limitation of not assessing a cause and effect relationship. The proposed study aims to evaluate only associative measures between the categorical variables of IR, use of stavudine, didanosine, and protease inhibitors in the presence of thyroid disease. These antiretrovirals were chosen based on previous publications and by the HAART profile, which was used in the hospital where the study was performed. The sample of HAART users as a whole had a history of using zidovudine and lamivudine, and these patients were excluded from the analysis.
Among HIV-infected individuals, approximately 1% to 2% has symptomatic thyroid disease, and up to 35% may have only subtle abnormalities in thyroid function tests (23) . In this study, 6.83% of patients had TSH values greater than 4.5 μUI/L and FT 4 values less than 0.9 ng/dL, which characterized them with primary hypothyroidism. These values were above the averages that had been published previously for HIV-infected individuals, in whom the prevalence was estimated from 2.6% up to 0.3% when compared with the general population (19) . Subclinical hypothyroidism is characterized by slightly elevated TSH and normal FT 4 levels. In the present study, 12.82% of patients had these characteristics, which kept this result above the average prevalence among HIV-infected persons of 3.5% to 12.2% (20) (21) (22) . This result was elevated with respect to the overall population, for which the prevalence is 4.3% (19) . We can link this response to the genetic and environmental profiles of the study population, issues related to the HIV genotype, or HAART profile history in the sample. Another possible reason is the lack of a definition in the literature relating the TSH baseline and ultrasensitive detection assay development. Further analysis of these assumptions may elucidate a mechanism for the high prevalence of primary hypothyroidism in this population.
Another important finding was the prevalence of > 34 μUI/L anti-TPO in 4% of patients who had anti-TPO measurements. From all of the patients who had anti-TPO measurements, 1% had increased TSH with normal FT 4 levels (subclinical hypothyroidism). In the other 1%, we identified isolated increased FT 4 (secondary hyperthyroidism) levels, and another 2% had normal thyroid function. In the general population, hypothyroidism is most commonly caused by autoimmune thyroid destruction, in which 90% of cases were anti-TPO positive (34) . In our study, only one of 23 patients was diagnosed with hypothyroidism or subclinical hypothyroidism and had positive anti-TPO values (4.34%). This value is below what is expected for the general population and gives consistency to the scientific evidence that HIV-infected patients with primary hypothyroidism have lower anti-TPO positivity (20, 32) . The absence of anti-TPO does not mean that the patients do not have thyroid autoimmune disease. Tissue biopsies and imaging tests, such as an ultrasound, are necessary to identify whether patients with anti-TPO also demonstrate an absence of lymphocytic infiltration and heterogeneous aspects of the gland, which are characteristic of Hashimoto's thyroiditis. The onset of Graves' disease appears to be possible after the IR. There are few case reports of Hashimoto's thyroiditis that developed after initiating HAART (35) . In the present study, there was an association of protection that was very close to reaching statistical significance that was related to thyroid disease in the presence of IR history. This trend suggests that most thyroid dysfunction in AIDS cases are not immunemediated but are related to specific antiretroviral drugs and the presence of disease activity as in the euthyroid sick syndrome.
The use of stavudine has been associated with subclinical hypothyroidism in a few studies. In one prospective study, abnormalities in thyroid function were found in 12.6%. Patients on stavudine had significantly lower FT4 levels with prolonged treatment (25) . In other study, the prevalence of subclinical hypothyroidism was 12.2% and the previous use of PI, especially stavudine, had a statistically significant risk association for hypothyroidism when compared to naïve patients (p < 0.05) (29) . As in the previously cited studies, an association of risk was observed among the historical use of stavudine and subclinical hypothyroidism OR = 4.19, 95%CI: 1.29 to 13.59, X² = 6.37, p = 0.01). The underlying mechanisms involved in this association are unclear and deserve further investigation. The association analysis between stavudine use and thyroid diseases (general thyroid diseases, pituitary/central hypothyroidism, euthyroid sick syndrome, secondary hyperthyroidism, primary hypothyroidism or subclinical hyperthyroidism) was not statistically significant.
Isolated low FT 4 levels with normal or low TSH levels are frequently observed among HIV-infected individuals with a prevalence of 1.3% to 6.8% (20, (26) (27) (28) . Within these results, the value in our study was higher than the average because 11.96% of patients had normal TSH and low FT 4 levels. In some cases, euthyroid sick syndrome or pituitary or hypothalamus failure can lead to central hypothyroidism (secondary or tertiary). In such cases, FT 4 concentrations are low, and TSH concentrations can be low or in the normal range.
In patients with low thyroid hormone levels and normal or low TSH (1 patient = 0.85%) levels, pituitary/central hypothyroidism or euthyroid sick syndrome needs to be considered. Euthyroid sick syndrome occurs during severe illnesses, including advanced AIDS, where the most common pattern of thyroid function is reduced T 3 levels, high rT 3 levels, varying FT 4 levels, and normal or decreased TSH levels, depending upon disease severity. However, a smaller increase of rT 3 levels was observed among patients with advanced AIDS (33) . During disease recovery, TSH levels may increase temporarily, sometimes exceeding the normal range, thus returning FT 4 and T 3 levels to normal values, mimicking subclinical hypothyroidism. Among the HIV--infected population, the highest frequency of thyroid disease was reported in patients with terminal AIDS before HAART, with up to 16% of patients affected (30) . In this study, TSH and FT 4 levels were obtained in low levels in only one patient (0.85%). rT3 measurement in individuals that are not suspected of having thyroid disease is not recommended and was not performed. The sum of patients with normal or low TSH and low FT 4 levels totaled 15 (12.82%), which was higher than expected for HIV (1.3% to 6.8%) (20, (26) (27) (28) .
We conclude that the prevalence of thyroid disease in the sample studied was higher than what had been found in the literature, with a low positive anti-TPO frequency. The historical use of stavudine has an association of risk for the presence of subclinical hypothyroidism, and IR has a protection association close to statistical significance for the presence of thyroid diseases. Disclosure: no potential conflict of interest relevant to this article was reported.
